Skip to content
OpenCapital
Get started

Esperion Therapeutics ESPR Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number at other companies

Organon logo
OrganonOGN
——
Viatris logo
ViatrisVTRS
——

Other financials

Income statement

See full
Revenue$80.1M+23.2%
Operating income-$6.6M+70.2%
Net income-$25.2M+37.7%
EPS (diluted)-$0.10+52.4%

Balance sheet

See full
Cash & equivalents$156.2M+36.2%
Total debt$155.2M+6.1%
Total equity-$307.9M+27.8%
Total assets$462.5M+42.7%

Cash flow

See full
Operating cash flow-$27.7M-22.5%
CapEx$189.0K—
Free cash flow-$27.9M-23.3%

Valuation

See full
Market cap$811.73M+283%
Enterprise value$810.81M+233%
P/S1.9×+1.1×

Profitability

See full
Operating margin18.1%+12.7pp
Net margin-34.8%+8.0pp
FCF margin-30.7%—

Returns & leverage

See full
Return on equity-260.8%—
Debt / equity0.8×—
Current ratio1.5×+0.4×

Where this comes from

Reported directly by Esperion Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber.

The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Esperion Therapeutics's share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, number.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Esperion Therapeutics's share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, number?
Esperion Therapeutics (ESPR) reported share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, number of $8.64M in Q1 2026.
How has Esperion Therapeutics's share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, number changed year-over-year?
Esperion Therapeutics's share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, number increased by 25.4% year-over-year, from $6.89M to $8.64M.
What is the long-term trend for Esperion Therapeutics's share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, number?
Over 2 years (2020 to 2025), Esperion Therapeutics's share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, number has grown at a 27.4% compound annual growth rate (CAGR), from $4.18M to $6.78M.